

S 2164

Lower Costs, More Cures Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 22, 2021

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Jun 22, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/2164>

Sponsor

Name: Sen. Crapo, Mike [R-ID]

Party: Republican • **State:** ID • **Chamber:** Senate

Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Burr, Richard [R-NC]	R · NC		Jun 22, 2021
Sen. Daines, Steve [R-MT]	R · MT		Jun 22, 2021
Sen. Ernst, Joni [R-IA]	R · IA		Jun 22, 2021
Sen. Marshall, Roger [R-KS]	R · KS		Jun 22, 2021
Sen. Risch, James E. [R-ID]	R · ID		Jun 22, 2021
Sen. Scott, Tim [R-SC]	R · SC		Jun 22, 2021
Sen. Tillis, Thomas [R-NC]	R · NC		Jun 22, 2021
Sen. Hoeven, John [R-ND]	R · ND		Sep 6, 2022

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jun 22, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 2815	Related bill	Sep 23, 2021: Read twice and referred to the Committee on Finance.
117 HR 4417	Related bill	Jul 14, 2021: Referred to the Subcommittee on Health.
117 HR 3682	Related bill	Jun 2, 2021: Referred to the Subcommittee on Health.
117 S 1287	Related bill	Apr 21, 2021: Read twice and referred to the Committee on Finance. (text: CR S2126-2127)

Lower Costs, More Cures Act of 2021

This bill establishes and modifies several programs and requirements to address prescription drug prices, particularly in relation to Medicare and Medicaid.

Among other changes, the bill

- requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
- caps annual out-of-pocket spending under the Medicare prescription drug benefit;
- allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region;
- establishes requirements under the Medicaid Drug Rebate Program for certain gene therapies for which prices are indexed to achieved outcomes; and
- establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.

Actions Timeline

- **Jun 22, 2021:** Introduced in Senate
- **Jun 22, 2021:** Read twice and referred to the Committee on Finance.